Clinical Trial Update: Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing NK-104-CR and Livalo IR in primary hyperlipidemia or mixed dyslipidemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hyperlipidemia

Drugs mentioned

• LIVALO (pitavastatin calcium)
• NK-104-CR

Snippet

Sponsor: Kowa Research Institute, Inc. | Conditions: Hyperlipidemia, Dyslipidemia | Phase 3 | Status: WITHDRAWN